801 related articles for article (PubMed ID: 28242667)
41. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
[TBL] [Abstract][Full Text] [Related]
42. Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying
Castanheira M; Mendes RE; Sader HS
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031200
[No Abstract] [Full Text] [Related]
43. Increased gene expression and copy number of mutated bla
Sun L; Li H; Wang Q; Liu Y; Cao B
BMC Microbiol; 2021 Aug; 21(1):230. PubMed ID: 34412588
[TBL] [Abstract][Full Text] [Related]
44. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
Zhang P; Hu H; Shi Q; Sun L; Wu X; Hua X; McNally A; Jiang Y; Yu Y; Du X
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0127922. PubMed ID: 36794957
[TBL] [Abstract][Full Text] [Related]
45. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
Shen Z; Ding B; Ye M; Wang P; Bi Y; Wu S; Xu X; Guo Q; Wang M
J Antimicrob Chemother; 2017 Jul; 72(7):1930-1936. PubMed ID: 28333323
[TBL] [Abstract][Full Text] [Related]
46. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
[TBL] [Abstract][Full Text] [Related]
47. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.
Kazmierczak KM; Biedenbach DJ; Hackel M; Rabine S; de Jonge BL; Bouchillon SK; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4490-500. PubMed ID: 27161636
[TBL] [Abstract][Full Text] [Related]
48. A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.
Piazza A; Mattioni Marchetti V; Bielli A; Biffignandi GB; Piscopiello F; Giudici R; Tartaglione L; Merli M; Vismara C; Migliavacca R
J Microbiol Immunol Infect; 2024 Jun; 57(3):457-469. PubMed ID: 38584042
[TBL] [Abstract][Full Text] [Related]
49. Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis.
Krithika VM; Ganesan V; Rajendran T
Indian J Med Microbiol; 2024; 49():100603. PubMed ID: 38705276
[TBL] [Abstract][Full Text] [Related]
50. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
[TBL] [Abstract][Full Text] [Related]
51. Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.
Nicola F; Cejas D; González-Espinosa F; Relloso S; Herrera F; Bonvehí P; Smayevsky J; Figueroa-Espinosa R; Gutkind G; Radice M
Microbiol Spectr; 2022 Dec; 10(6):e0373322. PubMed ID: 36445147
[TBL] [Abstract][Full Text] [Related]
52. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
Sader HS; Castanheira M; Jones RN; Flamm RK
Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
[TBL] [Abstract][Full Text] [Related]
53. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
[TBL] [Abstract][Full Text] [Related]
54. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant
Athans V; Neuner EA; Hassouna H; Richter SS; Keller G; Castanheira M; Brizendine KD; Mathers AJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30578403
[TBL] [Abstract][Full Text] [Related]
55. Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam.
Hobson CA; Bonacorsi S; Hocquet D; Baruchel A; Fahd M; Storme T; Tang R; Doit C; Tenaillon O; Birgy A
Sci Rep; 2020 Jan; 10(1):589. PubMed ID: 31953453
[TBL] [Abstract][Full Text] [Related]
56.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
57. Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.
Munoz-Price LS; Reeme AE; Buchan BW; Mettus RT; Mustapha MM; Van Tyne D; Shields RK; Doi Y
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332070
[TBL] [Abstract][Full Text] [Related]
58. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
Shen S; Tang C; Yang W; Ding L; Han R; Shi Q; Guo Y; Yin D; Hu F
Emerg Microbes Infect; 2024 Dec; 13(1):2356146. PubMed ID: 38743401
[TBL] [Abstract][Full Text] [Related]
59. Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity.
Oueslati S; Iorga BI; Tlili L; Exilie C; Zavala A; Dortet L; Jousset AB; Bernabeu S; Bonnin RA; Naas T
J Antimicrob Chemother; 2019 Aug; 74(8):2239-2246. PubMed ID: 31127297
[TBL] [Abstract][Full Text] [Related]
60. Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent
Zhao J; Pu D; Li Z; Zhang Y; Liu X; Zhuo X; Lu B; Cao B
Virulence; 2024 Dec; 15(1):2348251. PubMed ID: 38697754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]